Biogen Inc. (NASDAQ:BIIB) – Equities research analysts at SunTrust Banks issued their Q3 2017 EPS estimates for shares of Biogen in a research note issued on Wednesday. SunTrust Banks analyst Y. Suneja anticipates that the biotechnology company will earn $5.79 per share for the quarter. SunTrust Banks has a “Buy” rating and a $360.00 price target on the stock. SunTrust Banks also issued estimates for Biogen’s Q4 2017 earnings at $5.75 EPS, FY2017 earnings at $21.78 EPS, Q1 2018 earnings at $5.70 EPS, Q2 2018 earnings at $5.95 EPS, Q3 2018 earnings at $6.11 EPS, Q4 2018 earnings at $6.24 EPS, FY2018 earnings at $24.00 EPS, FY2019 earnings at $26.00 EPS, FY2020 earnings at $28.30 EPS and FY2021 earnings at $30.00 EPS.

Several other brokerages have also issued reports on BIIB. Mizuho reiterated a “neutral” rating and issued a $319.00 price target (up previously from $274.00) on shares of Biogen in a report on Wednesday, September 13th. BMO Capital Markets increased their price objective on Biogen from $328.00 to $377.00 and gave the stock a “market perform” rating in a research note on Wednesday, September 13th. Vetr raised Biogen from a “hold” rating to a “buy” rating and set a $346.83 price objective for the company in a research note on Thursday, September 7th. Royal Bank Of Canada began coverage on Biogen in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $319.00 price objective for the company. Finally, ValuEngine downgraded Biogen from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Fourteen analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $329.99.

COPYRIGHT VIOLATION NOTICE: “Biogen Inc. (BIIB) Expected to Post Q3 2017 Earnings of $5.79 Per Share” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/22/biogen-inc-biib-expected-to-post-q3-2017-earnings-of-5-79-per-share.html.

Shares of Biogen (NASDAQ:BIIB) opened at 315.03 on Friday. Biogen has a 12 month low of $244.28 and a 12 month high of $330.00. The firm has a market cap of $66.61 billion, a price-to-earnings ratio of 20.67 and a beta of 0.77. The company has a 50-day moving average price of $300.47 and a 200-day moving average price of $278.47.

Biogen (NASDAQ:BIIB) last announced its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.36 by $0.68. Biogen had a return on equity of 37.42% and a net margin of 28.10%. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same quarter last year, the firm earned $5.21 EPS. Biogen’s revenue for the quarter was up 6.4% compared to the same quarter last year.

In other news, EVP Susan H. Alexander sold 4,974 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total value of $1,442,509.74. Following the completion of the transaction, the executive vice president now directly owns 22,258 shares of the company’s stock, valued at $6,455,042.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Susan H. Alexander sold 7,758 shares of the firm’s stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $285.00, for a total value of $2,211,030.00. Following the completion of the transaction, the executive vice president now directly owns 27,232 shares of the company’s stock, valued at $7,761,120. The disclosure for this sale can be found here. 0.32% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Beacon Trust Co. boosted its stake in Biogen by 0.5% during the first quarter. Beacon Trust Co. now owns 1,135 shares of the biotechnology company’s stock valued at $328,000 after buying an additional 6 shares during the period. Guardian Life Insurance Co. of America boosted its stake in Biogen by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 839 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 6 shares during the period. Carroll Financial Associates Inc. boosted its stake in Biogen by 1.2% during the second quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 6 shares during the period. Trust Co. of Vermont boosted its stake in Biogen by 0.3% during the first quarter. Trust Co. of Vermont now owns 2,412 shares of the biotechnology company’s stock valued at $660,000 after buying an additional 7 shares during the period. Finally, Buckingham Capital Management Inc. boosted its stake in Biogen by 0.3% during the first quarter. Buckingham Capital Management Inc. now owns 2,452 shares of the biotechnology company’s stock valued at $670,000 after buying an additional 8 shares during the period. 87.65% of the stock is owned by institutional investors.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Earnings History and Estimates for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.